Items where Author is "Kermode, A. G."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 11.

(2026) Causal effects of multiple sclerosis therapies in left-truncated registry data. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 1052-1068. ISSN 1477-0970 (Electronic) 1352-4585 (Print) 1352-4585 (Linking)

(2026) Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry. Therapeutic Advances in Neurological Disorders. p. 17562864261430084. ISSN 1756-2856 (Print) 1756-2864 (Electronic) 1756-2856 (Linking)

(2026) Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study. Journal of Neurology Neurosurgery and Psychiatry. pp. 763-773. ISSN 0022-3050

(2026) Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry. Journal of Neurology. p. 15. ISSN 0340-5354

(2026) Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder. Neurology. p. 12. ISSN 0028-3878

(2026) Predicting disease progression in multiple sclerosis with clinically accessible information and technology. Journal of Neurology. p. 18. ISSN 0340-5354

(2026) Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study. Cns Drugs. pp. 1011-1025. ISSN 1172-7047

(2025) Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024). Multiple Sclerosis Journal. pp. 1088-1101. ISSN 1352-4585

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. ISSN 23327812 (ISSN)

(2024) A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology. p. 12. ISSN 0340-5354

This list was generated on Fri Oct 9 05:14:13 2026 +0330.